Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $22.50, for a total value of $22,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Benjamin Hohl also recently made the following trade(s):

• On Monday, April 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total transaction of $55,152.50.
• On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.72, for a total transaction of $346,080.00.
• On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.25, for a total value of $59,312.50.
• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $55,152.50.

Enliven Therapeutics Stock Performance

ELVN opened at $24.70 on Wednesday. The company has a fifty day moving average of $17.67 and a two-hundred day moving average of $14.89. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -11.28 and a beta of 1.05.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. SG Americas Securities LLC increased its position in shares of Enliven Therapeutics by 17.8% during the fourth quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock worth $187,000 after purchasing an additional 2,041 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after buying an additional 1,029 shares in the last quarter. Exchange Traded Concepts LLC raised its position in shares of Enliven Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after buying an additional 2,208 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after buying an additional 3,189 shares in the last quarter. Finally, AJOVista LLC acquired a new position in Enliven Therapeutics during the fourth quarter worth about $28,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Mizuho initiated coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective on the stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.